Literature DB >> 36193160

Full myocardial recovery following COVID-19 fulminant myocarditis after biventricular mechanical support with BiPella: a case report.

Silvia Ajello1, Francesco Calvo2, Cristina Basso3,4, Pasquale Nardelli1, Anna Mara Scandroglio1.   

Abstract

Background: Fulminant myocarditis is a rare yet dreadful condition, which requires evaluation for mechanical support. The concomitant use of an Impella pump in the left and of one in the right ventricle-the so-called 'BiPella approach'-might allow recovery of the failing heart in selected cases. We report a peculiar case, in which mechanical circulatory support was used as the sole strategy to promote myocardial recovery, without the administration of any immunosuppressants in coronavirus disease (COVID)-19 fulminant myocarditis. Case summary: A previously healthy 49-year-black man presented to the emergency department with dyspnoea and severe metabolic acidosis. His nasopharyngeal swab resulted positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Echocardiography documented severe biventricular dysfunction which required support with two Impella pumps-the so-called 'BiPella approach'. Myocarditis was suspected on clinical basis. Endomyocardial biopsy showed SARS-CoV-2 localization within the endothelial cells. No antiviral or immunosuppressive therapy was administered. After 10 days of support, the patient was weaned from both right- and left-ventricular supports as complete recovery of cardiac function and end-organ damage was observed. The patient was discharged from the intensive care unit after 15 days and discharged home 1 month after presentation. The patient had no further episodes of heart failure at 6 months follow up. Discussion: Prolonged mechanical unloading with two Impella pumps in fulminant COVID-19 myocarditis is a viable and reliable strategy, as it provides the benefits of mechanical circulatory support plus additional disease-modifying effects, reducing wall stress and inflammatory response.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  COVID-19; Case report; Fulminant myocarditis; Impella; Mechanical circulatory support

Year:  2022        PMID: 36193160      PMCID: PMC9494380          DOI: 10.1093/ehjcr/ytac373

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


  10 in total

Review 1.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.

Authors:  Vanessa M Ferreira; Jeanette Schulz-Menger; Godtfred Holmvang; Christopher M Kramer; Iacopo Carbone; Udo Sechtem; Ingrid Kindermann; Matthias Gutberlet; Leslie T Cooper; Peter Liu; Matthias G Friedrich
Journal:  J Am Coll Cardiol       Date:  2018-12-18       Impact factor: 24.094

2.  Successful heart transplantation for COVID-19-associated post-infectious fulminant myocarditis.

Authors:  Baptiste Gaudriot; Alexandre Mansour; Vincent Thibault; Mathieu Lederlin; Aurélie Cauchois; Bernard Lelong; James T Ross; Guillaume Leurent; Jean-Marc Tadié; Matthieu Revest; Jean-Philippe Verhoye; Erwan Flecher; Nicolas Nesseler
Journal:  ESC Heart Fail       Date:  2021-05-02

3.  Full percutaneous biventricular support with two Impella pumps: the Bi-Pella approach.

Authors:  Federico Pappalardo; Anna Mara Scandroglio; Azeem Latib
Journal:  ESC Heart Fail       Date:  2018-02-21

4.  Mode-of-action of the PROPELLA concept in fulminant myocarditis.

Authors:  Frank Spillmann; Sophie Van Linthout; Gunther Schmidt; Oliver Klein; Nazha Hamdani; Thomas Mairinger; Florian Krackhardt; Bastian Maroski; Thomas Schlabs; Sajjad Soltani; Stefan Anker; Evgenij V Potapov; Daniel Burkhoff; Burkert Pieske; Carsten Tschöpe
Journal:  Eur Heart J       Date:  2019-07-01       Impact factor: 29.983

5.  Fulminant myocarditis in a COVID-19 positive patient treated with mechanical circulatory support - a case report.

Authors:  Joanna-Maria Papageorgiou; Henrik Almroth; Mattias Törnudd; Henriëtte van der Wal; Georgia Varelogianni; Sofia Sederholm Lawesson
Journal:  Eur Heart J Case Rep       Date:  2020-12-30

6.  Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry.

Authors:  Curt J Daniels; Saurabh Rajpal; Joel T Greenshields; Geoffrey L Rosenthal; Eugene H Chung; Michael Terrin; Jean Jeudy; Scott E Mattson; Ian H Law; James Borchers; Richard Kovacs; Jeffrey Kovan; Sami F Rifat; Jennifer Albrecht; Ana I Bento; Lonnie Albers; David Bernhardt; Carly Day; Suzanne Hecht; Andrew Hipskind; Jeffrey Mjaanes; David Olson; Yvette L Rooks; Emily C Somers; Matthew S Tong; Jeffrey Wisinski; Jason Womack; Carrie Esopenko; Christopher J Kratochvil; Lawrence D Rink
Journal:  JAMA Cardiol       Date:  2021-05-27       Impact factor: 14.676

7.  Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units.

Authors:  Guillaume Hékimian; Mathieu Kerneis; Michel Zeitouni; Fleur Cohen-Aubart; Juliette Chommeloux; Nicolas Bréchot; Alexis Mathian; Guillaume Lebreton; Matthieu Schmidt; Miguel Hié; Johanne Silvain; Marc Pineton de Chambrun; Julien Haroche; Sonia Burrel; Stéphane Marot; Charles-Edouard Luyt; Pascal Leprince; Zahir Amoura; Gilles Montalescot; Alban Redheuil; Alain Combes
Journal:  Chest       Date:  2020-09-08       Impact factor: 9.410

Review 8.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

9.  Myocardial involvement in coronavirus disease 19.

Authors:  Ahmed Saleh; Akira Matsumori; Sherif Abdelrazek; Sara Eltaweel; Amjad Salous; Franz-Josef Neumann; Matthias Antz
Journal:  Herz       Date:  2020-11-20       Impact factor: 1.443

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.